FDA Considers Rescheduling Marijuana Off Schedule 1 List

The U.S. Food and Drug Administration has taken up a request by the Drug Enforcement Agency to study whether marijuana should remain classified as a Schedule 1 drug.

The study could lead to marijuana being removed from the Schedule 1 category of the Controlled Substances Act.

A reclassification would have a sweeping impact on the U.S. cannabis industry. It could eliminate the industry’s problems with banks and allow more states to legalize the plant.

It could also open the door for major corporations to enter the industry.

According to Douglas Throckmorton, Deputy Director for Regulatory Programs at the FDA, the agency will make a recommendation after conducting an “eight-factor analysis” that examines marijuana’s abuse potential, its pharmacological effect and risk to public health, among other factors. Throckmorton did not give a timeline for the study’s conclusion.

The FDA reviewed marijuana’s status for the DEA in 2001 and 2006 and recommended that it remain a Schedule 1 drug. But public and political sentiment toward the plant has changed greatly since 2006, and the shift could impact the FDA’s assessment.

Daily News | Ancillary Marijuana Companies | Briefs | Dispensary/Retail Store Business News | Legal & Regulatory News for Marijuana Businesses | Uncategorized


  1. Ken June 24, 2014
  2. Jimmy Limo June 24, 2014
  3. Tim June 24, 2014
  4. Nash June 24, 2014
  5. Thomas June 24, 2014
  6. David June 25, 2014
  7. Big Pimpin June 25, 2014
  8. Johnny Korell June 26, 2014
  9. Jeff Brown June 28, 2014
    • shaggy May 26, 2015
  10. Johnny Korell June 29, 2014
  11. linda warren June 30, 2014
  12. Thomas Sebert November 14, 2014
  13. Thomas December 15, 2014
  14. Kim Carter April 29, 2015
  15. michael pursh June 3, 2015

Leave a Reply

Your email address will not be published. Required fields are marked *

Please note: Comments are moderated by our editors who do their best to approve comments ASAP. As Marijuana Business Daily is focused on business, we approve comments that are specifically relevant to industry professionals. General opinions and questions about cannabis may not be posted.